Topic: chemotherapy

NICE changes its tune on J&J's Zytiga

The U.K. cost watchdogs at the National Institute for Health and Care Excellence have said they couldn't fund Johnson & Johnson's prostate cancer drug Zytiga for pre-chemo treatment because it was too expensive. Now J&J has stepped forward with some discounts, so NICE is changing its tune.